Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin-6

<p><b>Copyright information:</b></p><p>Taken from "Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin"</p><p>http://www.molecular-cancer.com/content/6/1/66</p><p>Molecular Cancer 2007;6():66-66.</p><p>Published online 22 Oct 2007</p><p>PMCID:PMC2134932.</p><p></p>g/ml, 10 μg/ml, 10 μg/ml, respectively) as indicated, either in the presence or absence of NAC (5 mM). Cell proliferation was determined by MTT assay 48 h thereafter. Absorbance values obtained with untreated cells maintained under identical conditions were taken as 100%. Data represent means of at least three independent experiments and bars indicate standard deviations. **, < 0.01 and *, < 0.05 compared to cells treated in the absence of NAC but otherwise maintained under identical conditions